Disease · MONDO_0011996

chronic myeloid leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic myeloid leukemia. Diseases, record MONDO_0011996. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011996

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic myeloid leukemia; Open Targets
Open Targets ID: MONDO_0011996; Open Targets
Other names: BCR-ABL Positive chronic myelogenous leukaemia, BCR-ABL Positive chronic myelogenous leukemia, CML, CML - chronic myelogenous leukaemia, CML - chronic myelogenous leukemia, chronic granulocytic leukemia, chronic myelocytic leukaemia, chronic myelocytic leukemia, chronic myelogenous leukaemia (CML), chronic myelogenous leukemia, chronic myelogenous leukemia (CML), chronic myelogenous leukemia, BCR-ABL1 Positive, chronic myelogenous leukemias, hematopoeitic - chronic myelocytic leukaemia (CML), hematopoeitic - chronic myelocytic leukemia (CML), leukimia, chronic myeloid, myeloid leukemia, chronic; Open Targets
Disease Ontology: DOID:0081088; Disease Ontology
Disease Ontology: DOID:8552; Disease Ontology
NCI Thesaurus: C3174; NCI Thesaurus
Orphanet: ORPHA:521; Orphanet
Highest stage of its drugs: Approval, for 14 of its 179 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs179

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NILOTINIB	CHEMBL255863	Small molecule	Approval	ClinicalTrials.gov and EMA Human Drugs	107	105	105	Drugs and targets
IMATINIB	CHEMBL941	Small molecule	Approval	EMA Human Drugs	103	96	96	Drugs and targets
DASATINIB ANHYDROUS	CHEMBL1421	Small molecule	Approval	DailyMed and EMA Human Drugs	70	65	65	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Approval	DailyMed	63	61	61	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Approval	DailyMed	35	33	33	Drugs and targets
DASATINIB	CHEMBL5416410	Small molecule	Approval	EMA Human Drugs and PMDA	29	27	27	Drugs and targets
ASCIMINIB	CHEMBL4208229	Small molecule	Approval	EMA Human Drugs	26	25	25	Drugs and targets
PONATINIB	CHEMBL1171837	Small molecule	Approval	ClinicalTrials.gov	25	25	25	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	EMA Human Drugs, at withdrawal	14	13	3	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Approval	DailyMed	8	7	7	Drugs and targets

1 to 10 of 179

See all 179 drugs

Targets211

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	20	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Approval	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	15	Bcr/Abl fusion protein inhibitor	Approval	https://conductscience.org/library/genes/613	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	8	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	7	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	7	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	6	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	5	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets

1 to 10 of 211

See all 211 targets

Trials548

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 13 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05286528	Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database		1,484	2023-10-27	Chronic Myeloid Leukaemia	BOSUTINIB, DASATINIB, IMATINIB, NILOTINIB, PONATINIB	Its record names the disease	ClinicalTrials.gov
NCT00333840	Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia	Phase 3	1,106	2013-10-14	Chronic Myelogenous Leukemia	CYTARABINE, IMATINIB, INTERFERON	Its record names the disease	ClinicalTrials.gov
NCT01061177	Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase	Phase 4	1,090	2017-02-24	CML in Chronic Phase	NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00471497	A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)	Phase 3	846	2013-06-17	Myelogenous Leukemia, Chronic	IMATINIB, NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00123474	Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML	Phase 3	724	2015-08-26	Myeloid Leukemia, Chronic, Chronic-Phase	DASATINIB ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT00123487	Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML	Phase 3	638	2014-10-22	Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive	DASATINIB ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT01743989	A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.	Phase 3	620	2021-07-15	Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)	NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00261846	Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias	Phase 2	571	2013-03-12	Chronic Myeloid Leukemia	BOSUTINIB	Its record names the disease	ClinicalTrials.gov
NCT00481247	A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia	Phase 3	547	2011-03-15	Myeloid Leukemia, Chronic	DASATINIB ANHYDROUS, IMATINIB	Its record names the disease	ClinicalTrials.gov
NCT02130557	A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Phase 3	536	2018-11-14	Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive	BOSUTINIB, IMATINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 548

See all 548 trials

Comparisons in its trials87

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Imatinib (STI571) vs IFN-a + Ara-C: Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)	226 of 551	163 of 533	1,084	NCT00333840	Trial comparisons
Dasatinib 140 mg QD vs Dasatinib 70 mg BID: serious adverse events	228 of 304	236 of 305	609	NCT00123487	Trial comparisons
Bosutinib vs Imatinib: deaths from any cause	14 of 268	14 of 268	536	NCT02130557	Trial comparisons
Bosutinib vs Imatinib: Number of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation	68 of 268	38 of 265	533	NCT02130557	Trial comparisons
Bosutinib vs Imatinib: serious adverse events	98 of 268	68 of 265	533	NCT02130557	Trial comparisons
Bosutinib vs Imatinib: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities	16 of 266	13 of 262	528	NCT02130557	Trial comparisons
Bosutinib vs Imatinib: Number of Participants With Vital Signs Abnormalities	107 of 262	109 of 263	525	NCT02130557	Trial comparisons
Dasatinib vs Imatinib: Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months	204 of 259	177 of 260	519	NCT00481247	Trial comparisons
Dasatinib vs Imatinib: serious adverse events	90 of 258	70 of 258	516	NCT00481247	Trial comparisons
Bosutinib vs Imatinib: serious adverse events	90 of 248	57 of 251	499	NCT00574873	Trial comparisons

1 to 10 of 87

See all 87 comparisons in its trials

Papers from its trials280

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42454992	RESULT	1	PubMed
37004981	RESULT	1	PubMed
35407407	RESULT	1	PubMed
34195988	RESULT	1	PubMed
33180106	RESULT	1	PubMed
30574454	RESULT	1	PubMed
29609532	RESULT	1	PubMed
29567798	RESULT	1	PubMed
29248669	RESULT	1	PubMed
29152138	RESULT	1	PubMed

1 to 10 of 280

See all 280 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011996

GET https://conductscience.org/api/diseases/v1/MONDO_0011996/drugs?page=2

API reference For AI assistants